Metrics & Benchmarks

Latest News


Funding Challenges in Creating Patient-Centric Trial Models
0:59
Funding Challenges in Creating Patient-Centric Trial Models

Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), discusses how rigid budgeting and limited sponsor-site dialog often block innovative patient-centric solutions.

5 days ago
by
Andy Studna, Senior Editor
How Patient Support Services Can Empower Underserved Populations
0:52
How Patient Support Services Can Empower Underserved Populations

Heather Horville, solutions consultant at Greenphire, discusses how upfront reimbursement, travel stipends, and flexible support services can empower more patients.

5 days ago
by
Andy Studna, Senior Editor
Challenges With DCT Adoption
0:34
Challenges With DCT Adoption

Sunny Kumar, MD, partner at Informed Ventures, explains how high upfront costs and limited proof of cost savings are slowing adoption of DCT models.

5 days ago
by
Andy Studna, Senior Editor
How Fundings Cuts are Impacting DEI in Clinical Research
0:31
How Fundings Cuts are Impacting DEI in Clinical Research

Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations.

19 days ago
by
Andy Studna, Senior Editor
Shifting Regulations for Vaccine Trials
0:48
Shifting Regulations for Vaccine Trials

Krinx Kong, chief commercial officer, Cognivia, discusses how trial design and timelines could be impacted by a shift in policies around vaccine studies.

19 days ago
by
Andy Studna, Senior Editor
2025 Executive Orders and Clinical Trials
0:55
2025 Executive Orders and Clinical Trials

Kate Gallin Heffernan, life sciences attorney at Epstein Becker Green, explains how recent executive orders are creating uncertainty around compliance for clinical research teams receiving federal funding.

19 days ago
by
Andy Studna, Senior Editor
Excitement Around Biomarkers in Clinical Trials
0:45
Excitement Around Biomarkers in Clinical Trials

Michael Miller, chief operating officer at Quanterix, discusses how the use of biomarkers is expanding beyond exploratory endpoints to inform efficacy and patient selection, driving improved outcomes and greater efficiency in clinical research.

19 days ago
by
Andy Studna, Senior Editor
Enhancing Trial Efficiency and Patient Safety With Remote Monitoring
0:46
Enhancing Trial Efficiency and Patient Safety With Remote Monitoring

Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, explains how clinical operations teams can use remote monitoring and connected technologies to reduce site burden, respond faster to emerging data, and improve both patient safety and trial outcomes.

19 days ago
by
Andy Studna, Senior Editor
FDA's Recent Scrutiny of Trial Design
0:32
FDA's Recent Scrutiny of Trial Design

Meri Beckwith, Co-CEO of Lindus Health, discusses a recent Complete Response Letter issued to Replimune, explaining how shifts in FDA reviewers can affect single-arm trial acceptance, especially in oncology settings where control groups may be deemed unethical.

19 days ago
by
Andy Studna, Senior Editor

Applied Clinical Trials June 2025

Check out the latest features and columns!

Applied Clinical Trials June 2025

Navigating the Intersection of Accessibility and Measurement Integrity in eCOA

Clinical research evolves to prioritize patient-centered outcomes, integrating accessibility standards in electronic data capture for inclusive clinical trials.

Navigating the Intersection of Accessibility and Measurement Integrity in eCOA

How AI and Regulation are Reshaping the Future of Drug Safety

Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing efficiency and safety.

How AI and Regulation are Reshaping the Future of Drug Safety

Podcasts



All News

In this episode of the Applied Clinical Trials Brief, Shipra Patel, global therapeutic area section head for endocrinology and global head of pediatrics at Parexel, shares insights on what makes a standout research partner, how cross-functional teams support GLP-1 studies, the role of real-world evidence, and why patient retention will be critical to shaping the future of obesity drug development.

Kate Gallin Heffernan, life sciences attorney at Epstein Becker Green, and Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discuss how proposed policy changes could limit federal research funding, create uncertainty for clinical trial organizations, and slow the development of future therapies.